Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis.
Radiotherapy is an effective treatment for some esophageal cancers, but the molecular mechanisms of radiosensitivity remain unknown. RUNX3, a novel tumor suppressor of gastric cancer, functions in transforming growth factor (TGF)-beta-dependent apoptosis. We obtained paired samples from 62 patients with advanced esophageal cancers diagnosed initially as T3 or T4 with image diagnosis; one sample was obtained from a biopsy before presurgical radiotherapy, and the other was resected in surgical specimens after radiotherapy. RUNX3 was repressed in 67.7% cases of the pretreatment biopsy samples and 96.7% cases of the irradiated, resected samples. The nuclear expression of RUNX3 was associated with radiosensitivity and a better prognosis than cytoplasmic or no RUNX3 expression (P<0.003); cytoplasmic RUNX3 expression was strictly associated with radioresistance. RUNX3 was downregulated and its promoter was hypermethylated in all radioresistant esophageal cancer cell lines examined. Stable transfection of esophageal cancer cells with RUNX3 slightly inhibited cell proliferation in vitro, enhanced the antiproliferative and apoptotic effects of TGF-beta and increased radiosensitivity in conjunction with Bim induction. In contrast, transfection of RUNX3-expressing cells with a RUNX3 antisense construct or a Bim-specific small interfering RNA induced radioresistance. Treatment with 5-aza-2'-deoxycytidine restored RUNX3 expression, increased radiosensitivity and induced Bim in both control and radioresistant cells. These results suggest that RUNX3 silencing promotes radioresistance in esophageal cancers. Examination of RUNX3 expression in pretreatment specimens may predict radiosensitivity, and induction of RUNX3 expression may increase tumor radiosensitivity.
Sakakura
C
C
Dept of Surgery and Regenerative Medicine, Div of Surgery and Physiology of the Digestive System, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi, Kamigyo-ku, Kyoto 602-8566, Japan. sakakura@koto.kpu-m.ac.jp
Miyagawa
K
K
Fukuda
K-I
KI
Nakashima
S
S
Yoshikawa
T
T
Kin
S
S
Nakase
Y
Y
Ida
H
H
Yazumi
S
S
Yamagishi
H
H
Okanoue
T
T
Chiba
T
T
Ito
K
K
Hagiwara
A
A
Ito
Y
Y
D000368:Aged; D001706:Biopsy; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000235:genetics* / Q000532:radiotherapy*; D002454:Cell Differentiation; D002467:Cell Nucleus / Q000378:metabolism; D050677:Core Binding Factor Alpha 3 Subunit / Q000235:genetics*; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000532:radiotherapy*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011836:Radiation Tolerance
D050677:Core Binding Factor Alpha 3 Subunit; C493729:Runx3 protein, human